Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 26 results.
User Information
Export Records
  1. 1.   The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling
  2. Ping, Y. F.; Yao, X. H.; Jiang, J. Y.; Zhao, L. T.; Yu, S. C.; Jiang, T.; Lin, M. C. M.; Chen, J. H.; Wang, B.; Zhang, R.; Cui, Y. H.; Qian, C.; Wang, J. M.; Bian, X. W.
  3. Journal of Pathology. 2011, Jul; 224(3): 344-354.
  1. 2.   ASPS-1, A Novel Cell Line Manifesting Key Features of Alveolar Soft Part Sarcoma
  2. Kenney, S.; Vistica, D. T.; Stockwin, L. H.; Burkett, S.; Hollingshead, M. G.; Borgel, S. D.; Butcher, D. O.; Schrump, D. S.; Shoemaker, R. H.
  3. Journal of Pediatric Hematology Oncology. 2011, Jul; 33(5): 360-368.
  1. 3.   Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1 alpha Expression in an AhR-Independent Fashion
  2. Terzuoli, E.; Puppo, M.; Rapisarda, A.; Uranchimeg, B.; Cao, L. A.; Burger, A. M.; Ziche, M.; Melillo, G.
  3. Cancer Research. 2010, Sep 1; 70(17): 6837-6848.
  1. 4.   Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion
  2. Santhanam, A. N.; Baker, A. R.; Hegamyer, G.; Kirschmann, D. A.; Colburn, N. H.
  3. Oncogene. 2010, Jul; 29(27): 3921-3932.
  1. 5.   Therapeutic Vulnerability of an In Vivo Model of Alveolar Soft Part Sarcoma (ASPS) to Antiangiogenic Therapy
  2. Vistica, D. T.; Hollingshead, M.; Borgel, S. D.; Kenney, S.; Stockwin, L. H.; Raffeld, M.; Schrump, D. S.; Burkett, S.; Stone, G.; Butcher, D. O.; Shoemaker, R. H.
  3. Journal of Pediatric Hematology Oncology. 2009 31(8): 561-570.
  1. 6.   Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells
  2. Calvani, M.; Trisciuoglio, D.; Bergamaschi, C.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2008 68(1): 285-291.
  1. 7.   Transcriptome of hypoxic immature dendritic cells: Modulation of chemokine/receptor expression
  2. Ricciardi, A.; Elia, A. R.; Cappello, P.; Puppo, M.; Vann, C.; Fardin, P.; Eva, A.; Munroe, D.; Wu, X. L.; Giovarelli, M.; Varesio, L.
  3. Molecular Cancer Research. 2008 6(2): 175-185.
  1. 8.   UVC inhibits HIF-1 alpha protein translation by a DNA damage- and topoisomerase I-independent pathway
  2. Rapisarda, A.; Melillo, G.
  3. Oncogene. 2007, Oct; 26(48): 6875-6884.
  1. 9.   Expression of hypoxia-inducible factor 1 alpha, hypoxia-inducible factor 2 alpha, and von Hippel-Lindau protein in epitheLiaL ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1 alpha is an independent prognostic factor in ovarian carcinoma
  2. Osada, R.; Horiuchi, A.; Kikuchi, N.; Yoshida, J.; Hayashi, A.; Ota, M.; Katsuyama, Y.; Melilo, G.; Konishi, I.
  3. Human Pathology. 2007, Sep; 38(9): 1310-1320.
  1. 10.   The role of ascorbate in the modulation of HIF-1 alpha protein and HIF-dependent transcription by chromium(VI) and nickel(II)
  2. Kaczmarek, M.; Timofeeva, O. A.; Karaczyn, A.; Malyguine, A.; Kasprzak, K. S.; Salnikow, K.
  3. Free Radical Biology and Medicine. 2007, Apr; 42(8): 1246-1257.
  1. 11.   Identification of a new natural camptothecin analogue in targeted screening for HIF-1 alpha inhibitors
  2. Klausmeyer, P.; McCloud, T. G.; Melillo, G.; Scudiero, D. A.; Cardellina, J. H.; Shoemaker, R. H.
  3. Planta Medica. 2007, Jan; 73(1): 49-52.
  1. 12.   Meeting report: Exploiting the Tumor Microenvironment for Therapeutics
  2. Melillo, G.; Semenza, G. L.
  3. Cancer Research. 2006, MAY 1; 66(9): 4558-4560.
  1. 13.   Expression of hypoxia inducible factor-1 alpha and 2 alpha in genetically distinct early renal cortical tumors
  2. Kim, C. M.; Vocke, C.; Torres-Cabala, C.; Yang, Y. F.; Schmidt, L.; Walther, M.; Linehan, W. M.
  3. Journal of Urology. 2006, May; 175(5): 1908-1914.
  1. 14.   Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity
  2. Kong, D. H.; Park, E. J.; Stephen, A. G.; Calvani, M.; Cardellina, J. H.; Monks, A.; Fisher, R. J.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2005, OCT 1; 65(19): 9047-9055.
  1. 15.   Topotecan blocks hypoxia-inducible factor-1 alpha, and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells
  2. Beppu, Y.; Nakamura, K.; Linehan, W. M.; Rapisarda, A.; Thiele, C. J.
  3. Cancer Research. 2005, JUN 1; 65(11): 4775-4781.
  1. 16.   Cited1 is a bifunctional transcriptional cofactor that regulates early nephronic patterning
  2. Plisov, S.; Tsang, M.; Shi, G. B.; Boyle, S.; Yoshino, K.; Dunwoodie, S. L.; Dawid, I. B.; Shioda, T.; Perantoni, A. O.; de Caestecker, M. P.
  3. Journal of the American Society of Nephrology. 2005, JUN; 16(6): 1632-1644.
  1. 17.   Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small-molecule screening and structural databases
  2. Covell, D. G.; Wallqvist, A.; Huang, R. L.; Thanki, N.; Rabow, A. A.; Lu, X. J.
  3. Proteins-Structure Function and Bioinformatics. 2005, MAY 15; 59(3): 403-433.
  1. 18.   Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
  2. Rapisarda, A.; Zalek, J.; Hollingshead, M.; Braunschweig, T.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Hewitt, S. M.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2004, OCT 1; 64(19): 6845-6848.
  1. 19.   Genetic basis of cancer of the kidney: Disease specific approaches to therapy
  2. Linehan, W. M.; Vasselli, J.; Srinivasan, R.; Walther, M. M.; Merino, M.; Choyke, P.; Vocke, C.; Schmidt, L.; Isaacs, J. S.; Glenn, G.; Toro, J.; Zbar, B.; Bottaro, D.; Neckers, L.
  3. Clinical Cancer Research. 2004, SEP 15; 10(18, Part 2 Suppl. S): 6282S-6289S.
  1. 20.   HIF-1 - An oxygen and metal responsive transcription factor
  2. Maxwell, P.; Salnikow, K.
  3. Cancer Biology & Therapy. 2004 3(1): 29-35.
  1. 21.   Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages
  2. Bosco, M. C.; Puppo, M.; Pastorino, S.; Mi, Z. H.; Melillo, G.; Massazza, S.; Rapisarda, A.; Varesio, L.
  3. Journal of Immunology. 2004 172(3): 1681-1690.
  1. 22.   DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1 alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX
  2. Kaluzova, M.; Kaluz, S.; Lerman, M. I.; Stanbridge, E. J.
  3. Molecular and Cellular Biology. 2004 24(13): 5757-5766.
  1. 23.   Regulation of the chemokine receptor CXCR4 by hypoxia
  2. Schioppa, T.; Uranchimeg, B.; Saccani, A.; Biswas, S. K.; Doni, A.; Rapisarda, A.; Bernasconi, S.; Saccani, S.; Nebuloni, M.; Vago, L.; Mantovani, A.; Melillo, G.; Sica, A.
  3. Journal of Experimental Medicine. 2003 198(9): 1391-1402.
  1. 24.   Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene
  2. Ma, W. B.; Tessarollo, L.; Hong, S. B.; Baba, M.; Southon, E.; Back, T. C.; Spence, S.; Lobe, C. G.; Sharma, N.; Maher, G. W.; Pack, S.; Vortmeyer, A. O.; Guo, C. F.; Zbar, B.; Schmidt, L. S.
  3. Cancer Research. 2003 63(17): 5320-5328.
  1. 25.   Anti-angiogenic activity of human endostatin is HIF-1- independent in vitro and sensitive to timing of treatment in a human saphenous vein assay
  2. Macpherson, G. R.; Ng, S. S. W.; Forbes, S. L.; Melillo, G.; Karpova, T.; McNally, J.; Conrads, T. P.; Veenstra, T. D.; Martinez, A.; Cuttitta, F.; Price, D. K.; Figg, W. D.
  3. Molecular Cancer Therapeutics. 2003 2(9): 845-854.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel